Copenhagen-based Symphogen is losing its long-time CEO Kirsten Drejer, who co-founded the Danish antibody specialist in 2000. In her place, erstwhile CFO Martin Olin is taking over the helm.
Epidarex Capital-backed respiratory disease start-up Enterprise Therapeutics has named biotech entrepreneur John Ford as its new CEO. Ford previously co-founded Xention, Ario Pharma, and Metrion Biosciences.
Confo Therapeutics wants to metamorphose from a tech company to a drug discovery company, and it has hired Cedric Ververken to guide the transition.
Diagnostics company Arquer Diagnostics Ltd (Sunderland, UK) has appointed Nadia Whittley as CEO, replacing Ian Campbell with immediate effect. Whittley will be responsible for launching the company’s MCM5-ELISA diagnostic test and the expanding the technology beyond bladder and prostate cancer.
Lars Fruergaard Jørgensen, currently executive vice president and head of Corporate Development at Novo Nordisk, will take over the helm of the Danish diabetes major. He takes over from long-time CEO Lars Rebien Sørensen.
Danish biotech Acesion Pharma has hired Jakob Dynnes Hansen as its Chief Financial Officer. He joins from Evolva, a Swiss biotech company, where he has been CFO since 2007.
PharmaMar is driving the expansion of its US operations. To this end, the company has appointed Pascal Besman to the newly created role of Chief Operation Officer of the marine-derived oncology drug developers US subsidiary, PharmaMar US.
The BIA has added three new members to the Board of Directors. Calchan CEO Brenda Reynolds (pictured), Immunocore Chief Business Officer Eva-Lotta Allan and Polar Capital’s Partner – Healthcare Dan Mahony will join the board of the British BioIndustry Association from January 2017.
Cologne-based biotech Ayoxxa Biosystems GmbH announces that Rodney Turner has assumed duties as the interim CEO. Prior CEO Andreas Schmidt has stepped down.
Dutch immuno-oncology company Merus has appointed John Crowley its Chief Financial Officer. Former CFO Shelley Margetson has been elevated to Chief Operating Officer.